Breast Cancer Type 2 Susceptibility Protein (BRCA2) is a critical tumor suppressor involved in the homologous recombination (HR) pathway of DNA double-strand break repair. Mutations in BRCA2 lead to homologous recombination deficiency (HRD), rendering cancer cells highly susceptible to DNA-damaging agents and synthetic lethal therapies.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for BRCA2 drug discovery and synthetic lethality screening. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | BRCA2 Recombinant Protein (BRC Repeats / DNA Binding Domain) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Optimized for protein-protein interaction (PPI) assays. |
View BRCA2 Products |
| Gene Delivery | BRCA2 Promise-ORF / Lentivirus Full-length ORF or target-specific shRNA for stable cell line construction and HRD modeling. |
View BRCA2 Products |
| Benchmark Ab | Anti-BRCA2 Recombinant Antibody Sequence-verified positive control for Western Blot, Immunofluorescence, and IP. |
View BRCA2 Products |
| Validator | BRCA2 siRNA Set For transient knockdown verification to induce a homologous recombination deficient (HRD) phenotype. |
View BRCA2 Products |
| Related Target A | PARP1 The primary synthetic lethal partner. PARP inhibitors (PARPi) selectively kill BRCA2-deficient cells. |
View PARP1 Products |
| Related Target B | RAD51 Directly interacts with BRCA2 BRC repeats; crucial mediator of homologous recombination and target for overcoming PARPi resistance. |
View RAD51 Products |
| Related Target C | POLQ Polymerase Theta; synthetic lethal target in BRCA2-deficient tumors, actively pursued to bypass PARPi resistance. |
View POLQ Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Large Protein Expression & Stability | Domain-specific truncations (BRC repeats, DBD) designed for high stability and solubility in E. coli or Insect expression systems. |
| HRD Model Generation | High-titer Lentivirus and validated siRNA pools designed for robust BRCA2 gene silencing across multiple cancer cell lines. |
| Lack of Controls | Sequence-verified clinical-grade benchmark antibodies and recombinant control proteins included. |
| False Positives in PPI Screening | High-purity (>95%), mass-spectrometry verified proteins ensure reliable binding kinetics in SPR/BLI assays. |
Live BRCA2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of BRCA2-deficient cancers represents one of the most successful applications of synthetic lethality in oncology. While direct pharmacological restoration of mutated BRCA2 remains a challenge due to its large size and complex scaffolding functions, drug discovery has pivoted toward exploiting BRCA2 deficiency. The clinical landscape is dominated by PARP inhibitors (olaparib, rucaparib, niraparib, talazoparib) in breast, ovarian, prostate, and pancreatic cancers.
As resistance to first-generation PARP inhibitors inevitably emerges—often via BRCA2 reversion mutations or replication fork protection pathways—the next wave of R&D is shifting focus. Current clinical and preclinical pipelines are heavily prioritizing novel synthetic lethal targets (such as POLQ, USP1, and RAD51 inhibitors) and combination regimens to overcome resistance and expand the therapeutic window.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PARPi) | AstraZeneca, GSK, Pfizer, Clovis Oncology | Ovarian, Breast, Prostate, Pancreatic Cancers | HRD validation models (Need high-efficiency Lentiviral shRNA/siRNA) |
| Small Molecule (POLQi) | Artios Pharma, Repare Therapeutics | PARPi-resistant BRCA-mutant Solid Tumors | Selectivity assays (Need recombinant POLQ and BRCA2 pathway proteins) |
| Small Molecule (RAD51i) | CYTE Technologies, Novartis | Refractory BRCA-deficient Tumors | PPI disruption assays (Need high-purity BRCA2 BRC repeat proteins) |